With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...

Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa ...

Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Zevaskyn ...

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...

The healthcare industry is experiencing a time of unprecedented change, impacting organizations across the country. In the face of these significant challenges, IMA Medical Group is taking proactive ...

LogicSource, the leader in procurement services and technology solutions, released its first-ever Q2 2025 Sourcing Trends Report this week. As the inaugural edition of a new quarterly series, the ...

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

In a significant advancement for the Recessive Dystrophic Epidermolysis Bullosa (RDEB) community, the U.S. Food and Drug ...

Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.